Halozyme Therapeutics Balance Sheet Health
Financial Health criteria checks 3/6
Halozyme Therapeutics has a total shareholder equity of $452.7M and total debt of $1.5B, which brings its debt-to-equity ratio to 332.3%. Its total assets and total liabilities are $2.1B and $1.7B respectively. Halozyme Therapeutics's EBIT is $477.0M making its interest coverage ratio 60.1. It has cash and short-term investments of $666.3M.
Key information
332.3%
Debt to equity ratio
US$1.50b
Debt
| Interest coverage ratio | 60.1x |
| Cash | US$666.31m |
| Equity | US$452.70m |
| Total liabilities | US$1.67b |
| Total assets | US$2.12b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RV7's short term assets ($1.1B) exceed its short term liabilities ($108.8M).
Long Term Liabilities: RV7's short term assets ($1.1B) do not cover its long term liabilities ($1.6B).
Debt to Equity History and Analysis
Debt Level: RV7's net debt to equity ratio (185.1%) is considered high.
Reducing Debt: RV7's debt to equity ratio has increased from 26% to 332.3% over the past 5 years.
Debt Coverage: RV7's debt is well covered by operating cash flow (26.8%).
Interest Coverage: RV7's interest payments on its debt are well covered by EBIT (60.1x coverage).